HEERLEN, Netherlands,
August 29, 2017 /PRNewswire/ --
Royal DSM, a global science-based company active in health,
nutrition and materials, informs its stakeholders that Thermo
Fisher Scientific Inc. has completed the acquisition of Patheon
N.V. (NYSE: PTHN), a company in which DSM held approximately
48.7 million ordinary shares.
(Logo:
http://photos.prnewswire.com/prnh/20160803/395298LOGO )
Thermo Fisher has acquired all
the shares of Patheon held by DSM for $35.00 per ordinary share in cash, resulting in a
transaction payment to DSM of approximately $1.7 billion in cash. DSM has hedged the currency
exposure of the transaction proceeds, thereby locking in cash
proceeds of around €1.5 billion. The book value of DSM's stake in
Patheon is approximately €0.3 billion. The transaction will result
in a net book profit of around €1.2bn in Q3 2017.
Together with the approximately €0.5 billion in cash that DSM
already received in recent years, including the proceeds from the
Initial Public Offering of Patheon, the total cash proceeds from
the divestment of DSM's custom manufacturing activities in Pharma
in 2014 amount to approximately €2.0 billion.
DSM - Bright Science. Brighter Living.™
Royal DSM is a global science-based company active in health,
nutrition and materials. By connecting its unique competences in
life sciences and materials sciences DSM is driving economic
prosperity, environmental progress and social advances to create
sustainable value for all stakeholders simultaneously. DSM delivers
innovative solutions that nourish, protect and improve performance
in global markets such as food and dietary supplements, personal
care, feed, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based
materials. DSM and its associated companies deliver annual net
sales of about €10 billion with approximately 25,000
employees. The company is listed on Euronext Amsterdam. More
information can be found at http://www.dsm.com.
For more information:
DSM Corporate Communications
Herman Betten
tel. +31-(0)-45-5782017
e-mail media.contacts@dsm.com
DSM Investor Relations
Dave Huizing
tel. +31-(0)-45-5782864
e-mail investor.relations@dsm.com
Forward-looking statements
This press release may contain forward-looking statements with
respect to DSM's future (financial) performance and position. Such
statements are based on current expectations, estimates and
projections of DSM and information currently available to the
company. DSM cautions readers that such statements involve certain
risks and uncertainties that are difficult to predict and therefore
it should be understood that many factors can cause actual
performance and position to differ materially from these
statements. DSM has no obligation to update the statements
contained in this press release, unless required by law. The
English language version of the press release is leading.
PDF -
http://mma.prnewswire.com/media/549892/DSM_informs_market_on_Patheon.pdf
PRN NLD
